MYOCET PHASE II
Clinical Trial Program
A phase I/II Study and Pharmacokinetics Study of Paclitaxel and Myocet® in combination with Herceptin® as first line treatment of patients with metastatic or locally advanced breast cancer and HER2 overexpresion
Phase I, Phase II
Status
Finished
Tumour subtype:
HER2+
Scenario
Locally Advanced or Metastatic
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
José Baselga, MD, PhD (Hospital Universitario Vall d'Hebron, Barcelona)
